Organisation paid for research Program year 2024 Source: CMS Open Payments

Central Care PA

Neither a doctor nor a teaching hospital

Research payments

$121,135

50 payments

Through program year 2024, Central Care PA is reported as receiving $121,135 in research payments, across 50 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $9,890 4
2023 Research $29,900 3
2022 Research $13,878 3
2021 Research $35,337 14
2020 Research $8,266 8
2019 Research $23,864 18

Breakdown

Who paid Research payments · program years 2019–2024
  1. Takeda Pharmaceuticals U.S.A., Inc. $49,800 10 payments
  2. Eli Lilly and Company $37,790 6 payments
  3. Janssen Research & Development, LLC $30,295 15 payments
  4. Pharmacyclics LLC, An AbbVie Company $3,250 19 payments
Studies the money was for Research payments · program years 2019–2024
  1. Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer $28,892 7 payments
  2. A Phase 3 Open-Label Randomized Study of Fixed Duration Pirtobrutinib (Loxo-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin Cll-322) $27,900 2 payments
  3. The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT $21,364 4 payments
  4. A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - MM Study $21,062 4 payments
  5. A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (Loxo-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin Cll-322) $9,890 4 payments
  6. A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - MM Study $7,374 2 payments
  7. Pcyc-1134M-Ca $2,500 14 payments
  8. A Prospective Multinational Study of Real Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI IMiD and CD38 Monoclonal Antibody Treatment $1,261 7 payments
  9. Pcyc-1134M-Ca $750 5 payments
  10. A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment $142 1 payment
What the money was spent on Research payments · program years 2019–2024
  1. Other $21,364 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record